Current Oncology Reports

, Volume 10, Issue 5, pp 393–403

Management of relapsed diffuse large B-cell lymphoma

Authors

  • Vaishalee Padgaonkar Kenkre
    • Section of Hematology/Oncology, Department of MedicineThe University of Chicago
Article

DOI: 10.1007/s11912-008-0061-4

Cite this article as:
Kenkre, V.P. & Smith, S.M. Curr Oncol Rep (2008) 10: 393. doi:10.1007/s11912-008-0061-4

Abstract

Despite more effective front-line regimens, a substantial portion of patients with diffuse large B-cell lymphoma relapse and require further therapy. Several trials have established the efficacy of autologous stem cell transplantation for relapsed diffuse large B-cell lymphomas, but the benefit has been largely restricted to patients with chemosensitive disease and low-risk features at the time of relapse. In an effort to improve outcomes following an autologous transplant, researchers are exploring several avenues, including improvement of salvage regimens, addition of radioimmunotherapy to preparative regimens, and application of posttransplant treatments to eliminate minimal residual disease. Allogeneic stem cell transplantation also appears promising, but there is much to learn about optimal patient selection and timing. This review outlines the current approach to the management of relapsed diffuse large B-cell lymphoma, with an emphasis on newer peritransplant therapies.

Copyright information

© Current Medicine Group LLC 2008